https://www.selleckchem.com/products/ABT-263.html
l of current and promising future strategies and discuss the importance of (renal) dosimetry in PRRT.Abemaciclib is the third cyclin-dependent kinase 4 and 6 inhibitor approved for the treatment of advanced or metastatic breast cancer. In humans, abemaciclib is extensively metabolized by CYP3A4 with the formation of three active metabolites N-desethylabemaciclib (M2), hydroxyabemaciclib (M2 and hydroxy-N-desethylabemaciclib (M18). These metabolites showed similar potency compared to the parent drug and were significantly abundant in p
Like
Comment
Share
